Login to Your Account



Reata Completes $32M Financing to Fund Studies of CKD Drug

By Catherine Hollingsworth


Friday, March 27, 2009
Reata Pharmaceuticals Inc. has the cash to fund a mid-stage trial of its lead drug candidate for advanced chronic kidney disease, now that the Irving, Texas-based company has completed a $32 million Series F financing. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription